Results
1 -
10 of
240C. Glidewell, G. Ferguson, R. M. Gregson and A. J. Lough.
3,6,9,16,19,22-Hexaazatricyclo[22.2.2.2]triconta-1(26),11(29),12,14(30),24,27-hexaene, C24H38N6, as a building block in supramolecular chemistry: structures in two and three dimensions, Acta Cryst. (2000). B56, 287-298Â Â Â Â P. I. Coupar, G. Ferguson and C. Glidewell.
Piperazine-4,4'-Sulfonyldiphenol (1/2): a Self-Assembled Channel Structure, Acta Cryst. (1996). C52, 3052-3055    J. van de Streek, J. Brüning, S. N. Ivashevskaya, M. Ermrich, E. F. Paulus, M. Bolte and M. U. Schmidt.
Structures of six industrial benzimidazolone pigments from laboratory powder diffraction data, Acta Cryst. (2009). B65, 200-211Â Â Â Â Theberge CR; Bednar RA; Bell IM; Zartman CB; Zhang XF; Graham SL; Vacca JP; Corcoran HA; Fay JF; Hershey JC; Johnston VK; Kane SA; Mosser S; Salvatore CA; Williams TM.
Potent benzimidazolone-based CGRP receptor antagonists., Bioorganic & medicinal chemistry letters Finley DR; Bell MG; Borel AG; Sall DJ; Shuker AJ; Stephens TW; Tinsley FC; Winter MA; Jesudason CD; Bloomquist WE; Cohen ML; Heiman ML; Kriauciunas A; Matthews DP; Miles T; Neel DA; Rito CJ.
Potent benzimidazolone based human beta(3)-adrenergic receptor agonists., Bioorganic & medicinal chemistry letters Lewis JA; Scott SA; Lavieri R; Buck JR; Selvy PE; Stoops SL; Armstrong MD; Brown HA; Lindsley CW.
Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity., Bioorganic & medicinal chemistry letters Bruncko M; Tahir SK; Song X; Petros AM; Tse C; Rosenberg SH; Elmore SW; Chen J; Ding H; Huth JR; Jin S; Judge RA; Madar DJ; Park CH; Park CM.
N-aryl-benzimidazolones as novel small molecule HSP90 inhibitors., Bioorganic & medicinal chemistry letters Lo HY; Nemoto PA; Kim JM; Hill-Drzewi M; Pullen SS; Takahashi H; De Lombaert S; Hao MH; Qian KC; Farrow NA; Albaugh DR; Fowler DM; Schneiderman RD; Michael August E; Martin L.
Benzimidazolone as potent chymase inhibitor: modulation of reactive metabolite formation in the hydrophobic (P1) region., Bioorganic & medicinal chemistry letters Omura H; Kawai M; Shima A; Iwata H; Ando K; Iwata Y; Ito F; Masuda T; Ohta A; Makita N; Omoto K; Sugimoto H; Kikuchi A.
The SAR studies of novel CB2 selective agonists, benzimidazolone derivatives., Bioorganic & medicinal chemistry letters Li Q; Li T; Woods KW; Gu WZ; Cohen J; Stoll VS; Galicia T; Hutchins C; Frost D; Rosenberg SH; Sham HL.
Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity., Bioorganic & medicinal chemistry letters